You are here:

MS in the Media - 19 October 2018

Published on

13 - 19 October 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

MS-SMART trial unsuccessful

An innovative trial of three potentially neuroprotective drugs (riluzole, amiloride and fluoxetine) has not found any of them to be effective in secondary progressive MS. 

Source: UCLH
Source: National MS Society (USA)

MS Trust link: Drugs in development

People with progressive MS need early support

Australian research compared how people with different type so of MS rated their symptoms. People with primary progressive MS scored all symptoms apart from cognition and vision as more severe than people whose MS was initially relapsing.  Scores tended to even out the longer people had had MS. The authors suggest more support early on in primary progressive MS is required

Source: MS Research Australia

MS Trust link: Primary progressive MS

PIP rules protest

A protest at the Houses of Parliament has drawn attention to the effect of changes to the rules on how far someone can walk to qualify for Personal Independence Payment on people living with MS.

Source: Daily Mail
Source: Metro

MS Trust link: Benefits

Is cannabis effective in MS?

A review of previous research trials of cannabis in MS found evidence of some efficacy for spasticity, pain and bladder symptoms

Source: Medical News Today

MS Trust link: Medicinal cannabis

The role of vitamin D unclear

Two reviews of previous research found no particular evidence that vitamin D supplements were helpful in people already diagnosed with MS, though in one researchers says there was a "hint at a potential clinically meaningful treatment effect".

Source: MS Research Australia

MS Trust link: Vitamin D

Pregabalin and gabapentin restrictions

Pregabalin and gabapentin have been moved to class C of the Misuse of Drugs Act following the rise in people putting themselves at risk by using them recreationally. Controls on prescriptions will become tighter

Source: Home Office

MS Trust link: Pregabalin
MS Trust link: Gabapentin

Statue by sculptor with MS unveiled

A statue of blinded WW1 soldiers has been unveiled in Manchester. The sculptor, Johanna Domke-Guyot, has MS

Source: Daily Express

MS Trust link: Life with MS stories

More MS risk genes identified

Seven more genes have been identified that contribute 5% to the risk of getting MS. Four of the seven are linked to immune function

Source: MS Research Australia

MS Trust link: MS research updates

Gut enzyme potentially linked to MS

Swiss research has identified an enzyme (GDP-L-fucose synthase) that is more common in people with MS and may promote an immune response

Source: Medical News Today

MS Trust link: MS research updates

Print this page